Disclosures for "Comparative Pharmacology of Ofatumumab vs Ocrelizumab in Humanized CD20 Transgenic Mice")
-
Marc Bigaud has received personal compensation for serving as an employee of Novartis Pharma.
-
Dr. Anthony has received personal compensation for serving as an employee of University of Oxford. Dr. Anthony has received personal compensation for serving as an employee of Somerville College Oxford. Dr. Anthony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Anthony has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroplast. Dr. Anthony has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Oxomics. The institution of Dr. Anthony has received research support from Numares. The institution of Dr. Anthony has received research support from MRC UK.
-
Mrs. Zipfel has nothing to disclose.
-
Tatjana Uffelmann has nothing to disclose.
-
Mrs. Vostiarova has nothing to disclose.
-
Mr. Engelhardt has nothing to disclose.
-
Dr. Nuesslein-Hildesheim has received personal compensation for serving as an employee of Novartis Pharma AG. Dr. Nuesslein-Hildesheim has stock in Novartis Pharma AG.
-
Bernd C. Kieseier, MD has nothing to disclose.